Published in Mol Biol Cell on January 12, 2005
ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J (2006) 3.05
ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell (2006) 2.73
DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev (2008) 2.40
Interactions of human mismatch repair proteins MutSalpha and MutLalpha with proteins of the ATR-Chk1 pathway. J Biol Chem (2009) 1.21
DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol (2006) 1.13
Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair. PLoS Genet (2008) 1.06
Targeting and processing of site-specific DNA interstrand crosslinks. Environ Mol Mutagen (2010) 1.05
CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol (2014) 1.05
TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood (2007) 1.01
Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem (2008) 0.97
Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut (2008) 0.94
The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol (2006) 0.91
Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells. J Biol Chem (2010) 0.89
Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol Pharmacol (2009) 0.89
Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol Biol Cell (2009) 0.89
Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One (2013) 0.86
O6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation. Integr Biol (Camb) (2012) 0.84
DNA mismatch repair and the DNA damage response. DNA Repair (Amst) (2015) 0.83
Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage. DNA Repair (Amst) (2009) 0.83
The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83
Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer. DNA Repair (Amst) (2015) 0.82
MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea. Br J Cancer (2009) 0.80
Human pluripotent stem cells have a novel mismatch repair-dependent damage response. J Biol Chem (2014) 0.79
Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. Mutat Res (2013) 0.79
Exonuclease 1 (Exo1) is required for activating response to S(N)1 DNA methylating agents. DNA Repair (Amst) (2012) 0.79
Drug-sensitive DNA polymerase δ reveals a role for mismatch repair in checkpoint activation in yeast. Genetics (2011) 0.76
Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents. Mutat Res Rev Mutat Res (2015) 0.75
MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine. Exp Cell Res (2009) 0.75
NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair. Blood Cancer J (2015) 0.75
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (2003) 20.13
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev (2001) 12.46
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev (2000) 11.49
Cell cycle control and cancer. Science (1994) 10.90
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (1998) 8.74
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science (1997) 8.43
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science (1997) 8.24
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res (1999) 7.82
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol (2001) 7.26
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature (2001) 6.73
mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell (1991) 6.25
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A (2000) 5.64
Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J (1998) 5.25
Rapid destruction of human Cdc25A in response to DNA damage. Science (2000) 4.74
Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature (1991) 4.54
Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol (2002) 4.27
Replication checkpoint enforced by kinases Cds1 and Chk1. Science (1998) 4.22
Multiple mutations and cancer. Proc Natl Acad Sci U S A (2003) 4.21
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A (2002) 4.06
Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res (1994) 3.63
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 3.49
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A (1993) 3.07
Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res (2000) 3.06
The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet (2002) 2.97
Recombinant ATM protein complements the cellular A-T phenotype. Oncogene (1997) 2.95
Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev (1998) 2.84
Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control. Proc Natl Acad Sci U S A (1998) 2.81
Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A (1996) 2.57
Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (1993) 2.57
cdc25+ encodes a protein phosphatase that dephosphorylates p34cdc2. Mol Biol Cell (1992) 2.56
The mismatch repair system is required for S-phase checkpoint activation. Nat Genet (2002) 2.55
A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.51
MPF localization is controlled by nuclear export. EMBO J (1998) 2.42
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J (2002) 2.39
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol (1999) 2.21
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev (2004) 2.20
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem (2003) 2.18
Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A (1990) 2.14
Regulating the onset of mitosis. Curr Opin Cell Biol (1999) 2.10
Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase. EMBO J (1982) 2.03
Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem (2000) 2.00
Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res (1997) 1.96
MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A (2003) 1.90
Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol (2000) 1.88
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem (2003) 1.84
An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res (2004) 1.81
Cell death, chromosome damage and mitotic delay in normal human, ataxia telangiectasia and retinoblastoma fibroblasts after x-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med (1981) 1.66
hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci U S A (1999) 1.63
Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J (2003) 1.60
Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res (1992) 1.54
Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanidine. J Biol Chem (1986) 1.53
Mik1 levels accumulate in S phase and may mediate an intrinsic link between S phase and mitosis. Proc Natl Acad Sci U S A (2000) 1.46
DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry (1994) 1.43
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol (1996) 1.42
Overproduction of human Myt1 kinase induces a G2 cell cycle delay by interfering with the intracellular trafficking of Cdc2-cyclin B1 complexes. Mol Cell Biol (1999) 1.35
Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev (2001) 1.35
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res (2002) 1.32
Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res (1995) 1.32
Short hairpin activated gene silencing in mammalian cells. Methods Mol Biol (2004) 1.28
Combinatorial control of cyclin B1 nuclear trafficking through phosphorylation at multiple sites. J Biol Chem (2000) 1.27
Regulation of mitotic inhibitor Mik1 helps to enforce the DNA damage checkpoint. Mol Biol Cell (2000) 1.25
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol (2003) 1.24
Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair (Amst) (2004) 1.12
ATM is activated in response to N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA alkylation. J Biol Chem (2002) 1.06
Phosphorylation of the cyclin b1 cytoplasmic retention sequence by mitogen-activated protein kinase and Plx. Mol Cancer Res (2003) 1.02
G1 arrest and cell-cycle-dependent clastogenesis in UV-irradiated human fibroblasts. Mutat Res (1994) 0.97
DNA replication arrest and tolerance to DNA methylation damage. Carcinogenesis (1994) 0.94
N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol Cancer (2004) 0.88
Extension of the pre-DNA synthetic phase of the cell cycle as a consequence of DNA alkylation in Chinese hamster cells: a possible mechanism of DNA repair. Chem Biol Interact (1971) 0.80
O6-methylguanine-DNA methyltransferase-defective human cell mutant: O6-methylguanine, DNA strand breaks and cytotoxicity. Carcinogenesis (1988) 0.79
Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature (1996) 3.37
The mismatch repair system is required for S-phase checkpoint activation. Nat Genet (2002) 2.55
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol (2007) 2.47
Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A (1996) 2.19
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem (2004) 1.88
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci U S A (1995) 1.52
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis (2006) 1.47
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res (2006) 1.20
Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell Biol (1998) 1.19
The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis (2008) 1.17
The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene (2004) 1.16
Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate (2009) 1.14
DNMT1 knockout delivers a strong blow to genome stability and cell viability. Nat Genet (2007) 1.12
Distance communication transfer of HIV prevention interventions to service providers. Science (2004) 1.12
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene (2002) 1.07
Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer (2009) 1.07
ATM is activated in response to N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA alkylation. J Biol Chem (2002) 1.06
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest (2008) 1.06
The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene (2004) 1.06
The ATM-SMC1 pathway is essential for activation of the chromium[VI]-induced S-phase checkpoint. Mutat Res (2004) 1.06
ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomes. Am J Physiol Cell Physiol (2010) 1.06
Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet (2010) 1.06
Protective effect of gallic acid against lindane induced toxicity in experimental rats. Food Chem Toxicol (2011) 1.04
Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. Oncogene (2002) 1.04
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood (2007) 1.01
Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev (2004) 1.00
The monofunctional alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine triggers apoptosis through p53-dependent and -independent pathways. Toxicol Appl Pharmacol (2005) 0.99
Immunofluorescence-based assay to identify modulators of the number of plasma membrane KCa3.1 channels. Future Med Chem (2010) 0.99
HIV prevention in Africa: programs and populations served by non-governmental organizations. J Community Health (2004) 0.98
Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol (2002) 0.98
DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem (2001) 0.97
Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem (2011) 0.95
Regulation of DNA-dependent protein kinase activity by ionizing radiation-activated abl kinase is an ATM-dependent process. J Biol Chem (2000) 0.94
WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis (2011) 0.93
Bisulfite sequencing of DNA. Curr Protoc Mol Biol (2010) 0.92
Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp Cell Res (2003) 0.92
MLH1- and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N'-nitro-N'-nitrosoguanidine. J Biol Chem (2007) 0.92
Ionizing radiation exposure results in up-regulation of Ku70 via a p53/ataxia-telangiectasia-mutated protein-dependent mechanism. J Biol Chem (2000) 0.91
Laser Raman and FTIR studies on Li+ interaction in PVAc-LiClO4 polymer electrolytes. Spectrochim Acta A Mol Biomol Spectrosc (2006) 0.91
Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res (2013) 0.88
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther (2011) 0.87
The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol (2010) 0.87
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem (2012) 0.87
The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol (2005) 0.86
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
HIV prevention programs of nongovernmental organizations in Latin America and the Caribbean: the Global AIDS Intervention Network project. Rev Panam Salud Publica (2005) 0.85
c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. Mol Pharmacol (2006) 0.84
The role of obesity in spontaneous temporal bone encephaloceles and CSF leak. Otol Neurotol (2012) 0.84
The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83
Lyn regulates the cell death response to ultraviolet radiation through c-Jun N terminal kinase-dependent Fas ligand activation. Exp Cell Res (2003) 0.82
Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling. Breast Cancer Res Treat (2015) 0.81
A yoga-based exercise program to reduce the risk of falls in seniors: a pilot and feasibility study. J Altern Complement Med (2008) 0.81
N-methyl-N'-nitro-N-nitrosoguanidine activates cell-cycle arrest through distinct mechanisms activated in a dose-dependent manner. Mol Pharmacol (2005) 0.79
The Compound Action Potential in Subjects Receiving a Cochlear Implant. Otol Neurotol (2016) 0.79
Exonuclease 1 (Exo1) is required for activating response to S(N)1 DNA methylating agents. DNA Repair (Amst) (2012) 0.79
N-methyl-N'-nitro-N-nitrosoguanidine activates multiple cell death mechanisms in human fibroblasts. DNA Cell Biol (2007) 0.77
MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine. Exp Cell Res (2009) 0.75
Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage. Br J Cancer (2000) 0.75
Retraction: Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate lyase signaling. Oncotarget (2015) 0.75
Cochlear Implantation in Cases of Unilateral Hearing Loss: Initial Localization Abilities. Ear Hear (2017) 0.75
Audiological Outcomes and Map Characteristics in Children With Perimodiolar and Slim Straight Array Cochlear Implants in Opposite Ears. Otol Neurotol (2017) 0.75
Surveillance after resection of vestibular schwannoma: measurement techniques and predictors of growth. Otol Neurotol (2014) 0.75
Factors Influencing Pediatric Cochlear Implant Outcomes: Carolina Sibling Study. Otol Neurotol (2019) 0.75
Prospective Evaluation of Patients Undergoing Translabyrinthine Excision of Vestibular Schwannoma with Concurrent Cochlear Implantation. Otol Neurotol (2017) 0.75
Bloodletting at Jing-well points decreases interstitial fluid flow in the thalamus of rats. J Tradit Chin Med (2016) 0.75
The effect of the dc bias voltage on the x-ray bremsstrahlung and beam intensities of medium and highly charged ions of argon. Rev Sci Instrum (2010) 0.75
The use of KTP laser in revision stapedectomy. Otol Neurotol (2012) 0.75
A Case-Case Analysis of Intralabyrinthine Schwannoma Versus Intracanalicular Vestibular Schwannoma. Otol Neurotol (2022) 0.75
Note: Studies on target placement in TE(111) cylindrical cavity of electron cyclotron resonance x-ray source for the enhancement of x-ray dose. Rev Sci Instrum (2010) 0.75
Effect of source tuning parameters on the plasma potential of heavy ions in the 18 GHz high temperature superconducting electron cyclotron resonance ion source. Rev Sci Instrum (2012) 0.75
Success of lateral graft technique for closure of tympanic membrane perforations. Otol Neurotol (2015) 0.75
Characterization of a novel natural cellulosic fiber from Prosopis juliflora bark. Carbohydr Polym (2012) 0.75
Note: Studies on x-ray production in electron cyclotron resonance x-ray source based on ridged cylindrical cavity. Rev Sci Instrum (2012) 0.75
Radiation-Induced Necrosis of the Temporal Bone: Diagnosis and Management. Otol Neurotol (2015) 0.75
[Study on the morphological damage and cell apoptosis of nerve tissue in mice exposed to benzo[a]pyrene]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi (2002) 0.75
A study of Malaiyur village ecosystem of Madurai district, Tamil Nadu (India). J Environ Biol (2001) 0.75
Development of autonomous gamma dose logger for environmental monitoring. Rev Sci Instrum (2012) 0.75
Studies of emittance of multiply charged ions extracted from high temperature superconducting electron cyclotron resonance ion source, PKDELIS. Rev Sci Instrum (2010) 0.75
Frequency-to-Place Mismatch: Characterizing Variability and the Influence on Speech Perception Outcomes in Cochlear Implant Recipients. Ear Hear (1) 0.75